What is Zai Lab's upcoming event about?

Zai Lab will hold a conference call and webcast on October 24, 2024, to discuss data from a Phase 1 clinical trial of ZL-1310.

When is the conference call and webcast scheduled?

The conference call and webcast will take place at 8:30 a.m. ET (8:30 p.m. HKT) on October 24, 2024.

Is advance registration required to participate in the conference call?

Participants must register in advance to access the conference call and webcast.

How can participants access the live webcast?

Listeners can access the live webcast by visiting Zai Lab's investor relations website.

What areas does Zai Lab focus on in its research and development?

Zai Lab is focused on developing innovative products in areas like oncology, immunology, neuroscience, and infectious disease, targeting significant unmet medical needs.

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

10/17/24 8:00:00 AM ET

$ZLAB

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ZLAB alert in real time by email

Company to host conference call and webcast on October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT), following plenary oral presentation of data at the EORTC-NCI-AACR Symposium (ENA) 2024

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) today announced that it will hold an investor webcast to discuss data from a Phase 1 clinical trial of ZL-1310, the Company's investigational DLL3-targeted antibody-drug conjugate (ADC), in patients with advanced stage small cell lung cancer (SCLC). The live conference call and webcast will take place on Thursday, October 24, 2024, at 8:30 a.m. ET (8:30 p.m. HKT).

Conference Call and Webcast Information

Listeners may access the live webcast by visiting the Company's website at http://ir.zailaboratory.com. Participants must register in advance of the conference call.

Details are as follows:

Registration Link: https://register.vevent.com/register/BI6f8ba8dc42d04cd3afd7095cf7c83d40

All participants must use the link provided above to complete the online registration process in advance of the conference call. Dial-in details will be in the confirmation email which the participant will receive upon registering.

A replay will be available shortly after the call and can be accessed by visiting the Company's website.

About Zai Lab

Zai Lab Limited (NASDAQ:ZLAB, HKEX: 9688))) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241017107131/en/

Get the next $ZLAB alert in real time by email

Recent Analyst Ratings for

$ZLAB

Date	Price Target	Rating	Analyst
3/7/2025	$55.00	Sector Outperform	Scotiabank
3/3/2025	$29.00 → $36.10	Buy → Neutral	BofA Securities
12/14/2023	$47.50	Overweight	Morgan Stanley
8/10/2023	$70.00	Overweight	Cantor Fitzgerald
3/2/2022	$194.00 → $102.00	Outperform	SVB Leerink
1/21/2022	$64.00	Outperform	Macquarie
12/15/2021	$189.00 → $136.00	Overweight	JP Morgan
11/11/2021	$222.00 → $217.00	Buy	Citigroup

More analyst ratings

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Chat with this insight

Q&A

What is Zai Lab's upcoming event about?

When is the conference call and webcast scheduled?

Is advance registration required to participate in the conference call?

How can participants access the live webcast?

What areas does Zai Lab focus on in its research and development?

Recent Analyst Ratings for
$ZLAB

$ZLAB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Wirth Peter was granted 10,831 units of American Depositary Shares, increasing direct ownership by 3% to 393,750 units (SEC Form 4)

Director Morrison Scott W was granted 10,831 units of American Depositary Shares, increasing direct ownership by 46% to 34,533 units (SEC Form 4)

Director Moulder Leon O Jr was granted 10,831 units of American Depositary Shares, increasing direct ownership by 18% to 72,602 units (SEC Form 4)

$ZLAB
Leadership Updates

Live Leadership Updates

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

$ZLAB
Press Releases

Fastest customizable press release news feed in the world

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Zai Lab to Host Webcast Presentation to Discuss Data from Early Clinical Program Evaluating Its Investigational DLL3-Targeted Antibody-Drug Conjugate (ADC) ZL-1310

Chat with this insight

Q&A

What is Zai Lab's upcoming event about?

When is the conference call and webcast scheduled?

Is advance registration required to participate in the conference call?

How can participants access the live webcast?

What areas does Zai Lab focus on in its research and development?

Recent Analyst Ratings for $ZLAB

$ZLAB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Wirth Peter was granted 10,831 units of American Depositary Shares, increasing direct ownership by 3% to 393,750 units (SEC Form 4)

Director Morrison Scott W was granted 10,831 units of American Depositary Shares, increasing direct ownership by 46% to 34,533 units (SEC Form 4)

Director Moulder Leon O Jr was granted 10,831 units of American Depositary Shares, increasing direct ownership by 18% to 72,602 units (SEC Form 4)

$ZLAB Leadership Updates

Live Leadership Updates

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

Zai Lab Appoints Michel Vounatsos To Its Board of Directors

Zai Lab Announces the Appointment of Dr. Rafael G. Amado as President, Head of Global Oncology Research and Development

$ZLAB Press Releases

Fastest customizable press release news feed in the world

Zai Lab Presents New Preclinical Data for ZL-1503, an IL-13/IL-31R Bispecific Antibody for the Treatment of Atopic Dermatitis, at EAACI Congress 2025

Zai Lab Presents Positive Phase 1 Data for ZL-1310, a DLL3-Targeted ADC, Demonstrating Robust Anti-Tumor Activity and Safety in Patients with Extensive-Stage Small Cell Lung Cancer at 2025 ASCO Annual Meeting

Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting

Recent Analyst Ratings for
$ZLAB

$ZLAB
Insider Trading

$ZLAB
Leadership Updates

$ZLAB
Press Releases